BioMedNewsBreaks

MondayJul 20, 2020 11:17 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Enters Strategic Agreement to Offer World-Class RPM Solution to HCPs Across the UK and Ireland

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced its entry into a new strategic partnership with Williams Medical to make the DarioHealth Remote Patient Monitoring (“RPM”) digital therapeutics platform available to Healthcare Professionals (“HCPs”) across the United Kingdom and Ireland. According to the update, Dario's turn-key RPM solution integrates the company's existing open platform, application technology, and the DarioEngage coaching platform, to allow Healthcare Professionals to monitor their patients remotely. "We are very excited about this partnership between DarioHealth and Williams Medical, as this aligns with our international growth initiative by offering our world-class RPM…

Continue Reading

ThursdayJul 16, 2020 12:32 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. Arms Clinicians, Targets Global OSA Market with Alternative Solutions

Vivos Therapeutics, an emerging leader in the treatment of obstructive sleep apnea (“OSA”), is positioned to capitalize on the growing global OSA market, projected to reach $13.24 billion by 2027. The company’s unique approach is to arm clinicians in treating patients suffering from OSA. A recent article discussing this reads, “The company’s oral appliances have proven to be effective in more than 15,000 patients successfully treated worldwide by approximately 1,350 trained dentists. Vivos’ vision is to provide clinicians with the tools to provide the best alternative solution to treat OSA.” To view the full article, visit http://ibn.fm/ge0Jr About Vivos Therapeutics…

Continue Reading

TuesdayJul 14, 2020 11:45 am

BioMedNewsBreaks – Why DarioHealth Corp. (NASDAQ: DRIO) Is ‘One to Watch’

DarioHealth (NASDAQ: DRIO) is a pioneer in the global digital therapeutics market focused on delivering evidence-based interventions to people with chronic conditions. A recent article discussing DarioHealth reads, “Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.” To view the full article, visit http://ibn.fm/QtIUL About DarioHealth Corp. DarioHealth is a leading, global, digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality…

Continue Reading

TuesdayJul 14, 2020 11:03 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Board Appointments

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of three new members to the company’s board of directors, effective immediately. According to the update, joining the board as independent directors are: Dr. Nancy Chung-Welch, Ph.D., Charles L. Nuzum, CPA and Greg St. Clair. “These appointments signify our absolute commitment to aligning our Board’s expertise with the company’s strategic vision of developing and commercializing an offering that will enable us to support the improvement in healthcare outcomes for oncology patients and increase value to our shareholders,”…

Continue Reading

FridayJul 10, 2020 1:50 pm

BioMedNewsBreaks – Vivos Therapeutics Inc.’s Innovative System Leverages Multidisciplinary Protocol in OSA Treatment

Vivos Therapeutics’ proprietary Vivos System(R) leverages a multidisciplinary treatment protocol comprised of comfortable oral devices and other therapies as needed. Over the course of treatment, typically ranging from 18 to 24 months, most patients experience an increased and enhanced upper airway with the purpose of reducing tissue obstructions causing obstructive sleep apnea (“OSA”). A recent article discussing this reads, “Vivos Therapeutics Inc. offers a new and superior alternative for treating obstructive sleep apnea, and the company believes its technology represents the most important breakthrough in OSA treatment since Continuous Positive Airway Pressure (‘CPAP’), which involves the use of special face…

Continue Reading

ThursdayJul 09, 2020 1:07 pm

BioMedNewsBreaks – CRISPR Therapeutics (NASDAQ: CRSP) Secures $517.5M in Underwritten Public Offering

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, has closed an underwritten public offering of 7,392,857 common shares, including 964,285 additional shares per the full exercise of the over-allotment option granted to the underwriters. CRISPR Therapeutics secured approximately $517.5 million in gross proceeds, with each of the shares sold at the public offering price of $70.00. ROTH Capital Partners acted as co-manager for the offering. For more information, visit www.CRISPRtx.com. About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its…

Continue Reading

TuesdayJul 07, 2020 12:40 pm

BioMedNewsBreaks – InvestorBrandNetwork Announces Launch of Technology-Driven Communications Platform – BioMedWire

InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, today announced the launch of BioMedWire (“BMW”) as part of its sustained effort to provide specialized content distribution via widespread syndication channels. A laser-focused, technology-driven communications platform, BioMedWire is designed to provide the latest updates and information related to emerging market opportunities in the life sciences sector and beyond. “The life sciences sector has delivered incredible remedies and cures, saved and changed lives, and offered some of the greatest investment returns the markets have ever seen. The sector is constantly moving and evolving to meet…

Continue Reading

TuesdayJul 07, 2020 10:47 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Completes Acquisition of Quantitative Medicine LLC

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced it has completed its acquisition of Quantitative Medicine LLC (“QM”), a biomedical analytics and computational biology company, in an all-stock transaction valued at approximately $1.8 million. Cofounded by Drs. Robert Murphy and Joshua Kangas, both of Carnegie Mellon University’s Computational Biology Department, QM developed its novel, computational drug-discovery platform CoRETM, an innovative machine learning platform that predicts the main effects of drugs on target molecules that mediate disease, which is expected to dramatically reduce the time, cost and financial…

Continue Reading

WednesdayJun 24, 2020 12:19 pm

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Participate Live on “The Big Biz Show”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that its CEO and Chairman, Rodney Varner, will be participating in a live interview with the “Big Biz Show,” an Emmy Award winning nationally syndicated TV and radio show, on Thursday, June 25. The Big Biz Show, seen and heard in over 100 million broadcast TV homes, 150 U.S. radio stations and in 175 countries, covers current business events, internet-related issues and other hot topics in the business world. Among several engaging topics, Varner will discuss how Genprex is bridging…

Continue Reading

FridayJun 19, 2020 1:46 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. Develops Potential, Nonsurgical Solution for Obstructive Sleep Apnea

Vivos Therapeutics, an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), has developed a groundbreaking remedy that holds the potential to be a possible solution for the life-threatening condition. A recent article further discussing the company reads, “This innovative medical device technology company has created and patented a novel system to combat OSA caused by deficiencies and other tissue anomalies in craniofacial anatomy development — the root cause behind 98% of OSA cases. The Vivos System requires no surgery but is a multidisciplinary treatment protocol that consists of comfortable and customized oral devices.  Over the typical 18-to-24-month…

Continue Reading